Author

De-Pei Wu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Oct 2026

Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.

BACKGROUND Complement-dependent cytotoxicity (CDC) of CD38 monoclonal antibodies has been associated with infusion-related reactions and might contribute to reduced clinical efficacy of CDC-reliant CD38 antibodies, particularly in patients with relapsed or refractory multiple myeloma with 1q21+. We aimed to evaluate fe...

Hai-Yan He, J. Shang, Ya-Fei Wang et al. · The Lancet Haematology · 0 citations

Case report Open access Sep 2026

Case Report: Central nervous system infiltration after allogeneic hematopoietic stem cell transplantation in high-risk myelodysplastic neoplasms

Background Although central nervous system leukemia (CNSL) is a recognized complication of acute leukemia, myelodysplastic neoplasms (MDS) complicated by CNSL are exceedingly rare, particularly after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous studies have largely focused on chronic myelomo...

Le-Jian Shi, Jinjin Zhu, Yu-Hang Wang et al. · Frontiers in Oncology · 0 citations